M. Cavallini, M. Papagnitaining long chain polynucleotides gel. The productmust be injected into the su<strong>per</strong>ficial dermaand the integration between the gel and thematrix of the dermis optimize the biore v a l i z a t i o naction of the skin.The purpose of this study is to describe the clinicalex<strong>per</strong>ience on skin biorevitalization withlong chain polynucleotides gel, focusing ons a f e t y, tolerability, techniques and clinical eff e c t s .atients and methodsPThe productP l i n e s t ® is a gel, consisting of highlypurified - natural origin long chain polynucleotides(20 mg/ml concentration) (4). It is markedin pre-filled glass syringe with 1.3 ml of highmolecular weight sterile and apirogenic polynucleotides.It is a class III medical device, biocompatible,of natural origin and allergy testingis not necessary. The product underwent manyin vitro and in vivo tests, showing the absence oflocal and systemic toxicity respecting the UNIrules of medical devices (cytotoxicity for dire c tcontact, allergic sensitization, mutagenicity test-Ames test, intracutaneous re a c t i v i t y, Irritationtest). In the clinical use it is noted a high tolerabilityand total absence of important side eff e c t s .Infiltration techniquesP l i n e s t ® is a handy product that can beinjected into derma with very thin needles(30G), which greatly reduce any discomfort tothe patient. The implant techniques used were :the serial puncture injections (micro whealstechnique), the re t rograde linear injections andthe cross-link technique.the serial puncture technique or micro whealstechnique consists of serial intra dermal injectionsevery 0,5-1 cm of small quantity of thep roduct to cover all the area to treat. This t e c h-nique can be used to treat the skin in every partof the face and of the body.the linear technique consists in the filling ofsu<strong>per</strong>ficial and/or medium dermis, followingthe wrinkles or the Langer lines, or in larg ea reas as the cheek or in the nasolabial folds.the cross-link technique consists of a net oflinear intersecting infiltrations. It allows thep roduct to distribute over the whole area, andis mainly suggested for treating larger areas, forinstance the cheek re g i o n .P a t i e n t sF rom June 2005 to May <strong>2007</strong>, 148patients of both sexes (134 females and 14males), with ages ranging from 32 to 75 years,w e re treated with long chain polynucleotides forskin biore v i t a l i z a t i o n .Inclusion criteria included: healthy patients, agesranging from 18 to 75 years, written informedconsent, five or more years of school, phototypeI-IV and if female not in pregnancy or bre a s t - f e e-ding. Exclusion criteria included: severe concomitantdiseases, hy<strong>per</strong>sensitivity to the product ins t u d y, abuse of alcohol or other drugs andsmoking (>20 cigarettes a day). Clinical evaluationswere carried out before treatment (T0) and30 days after the end of the initial treatment phase(follow up visit). The treatment efficacy was evaluatedby patient and physician assessment andby the analysis of digital pictures. The objectiveand subjective tolerability of the product usedwas evaluated during each intradermal infiltration.The physician assessment was evaluatedwith a quartiles scale (worsened, unchanged,i m p roved, highly improved) (5). The patientssatisfaction rate was evaluated during the followupvisit and has been re c o rded with a 0-10 visualanalogue scale (VAS) with 0 designated as theabsence of improvement and 10 the best improvementwith the best satisfaction of the patient.The VAS was chosen because it is easily administ e red and is well accepted by patients (6).Treated areasFace 132Neck 55Décolleté 14Back of the hands 9Total 210Table 1. Treated areas.Figure 1. Physician global assessment.28Journal of Plastic Dermatology <strong>2007</strong>; 3, 3
Long chain polynucleotides gel and skin biorevitalizationBEFOREAFTERFigure 2. a) Patient before neck treatment with long chain polynucleotides; b) The same patient one month after four treatments with long chainpolynucleotides. A reduction of fine wrinkles, an improvement of tonicity and appearance of the skin are shown.M o re o v e r, in 14 cases a digital skin measure m e n tsystem (Callegari Soft 5,5) was used to determine,p re and post-treatment, skin surface hydrationlevel, skin surface sebum content and skin pHlevel. The evaluation of the elasticity of the skinwas evaluated with the principle of stress anddeformation of skin by suction application.Negative pre s s u re is created into the device, ism e a s u red the resistance of the skin to be suckedup by negative pre s s u re (7, 8). This parameter isslightly lower in dense and supple skin, likeyoung skin, while it is higher in adult skin, wherethe carrying structure of derma is compro m i s e dand cannot oppose resistance to an applied forc e .Protocols of treatmentTwo diff e rent protocols of tre a t m e n thave been used: 1) prevention treatment, foryounger skin, consisting of a 3 infiltrations tre a t-ment - one every 3 weeks - followed by a maintenancetreatment every 2-3 months, and 2) re c o-v e ry treatment, a stronger treatment for agingskin, consisting of 4 infiltrations treatment, onee v e ry 1-2 weeks, followed by maintenance sessionsevery 1-3 months. An average of 1 or 2ready to use glass syringes are re q u i red <strong>per</strong> applica t i o n .R esults148 patients of both sexes (134 femalesand 14 males), were treated with long chainpolynucleotides for skin biorevitalization, meanage 46 years (from 32 to 75 years). Five patientsdid not complete the investigations with the follow-upvisit for reasons independent of thestudy, therefore 143 patients could be evaluated.In most cases (91 patients) only one skinarea was treated, in 37 patients two skin areaswere treated simultaneously and in the othercases (15 patients) more than two skin areaswere treated simultaneously. The face was theskin area more frequently treated (132patients), other treated areas were neck, décolletéand back of the hands (Table 1).The patients’ satisfaction rate, mean score ofVAS evaluation, was 7.1. This subjective judgmentwas confirmed by the analysis of pre andpost-treatment digital pictures.The physician global assessment during the follow-upvisit (Figure 1) was positive. In fact in91% of the patients the physician noted a clinicalimprovement (73% improved and 18%highly improved), due to the reduction ofsu<strong>per</strong>ficial fine wrinkles and to a better aspectof the skin that showed to be more tonic. Inparticular this result was noted in the treatmentof the face, above all in the check, <strong>per</strong>ioculararea and neck (Figures 2a-2b).It has been pointed out that in the days immediatelyfollowing infiltration it is clinicallyobserved an increase in turgidity of the skin,but the best clinical results are visible approximatelyone month after treatments, thanks tothe specific mechanism of action that promotean increase in the number of fibroblasts andtheir metabolic activation.Journal of Plastic Dermatology <strong>2007</strong>; 3, 329
- Page 1: Vol. 3, n. 3, September-December 20
- Page 4: L’istopatologia ed il foto-invecc
- Page 10: P. Filecciaammesso nelle formulazio
- Page 13 and 14: A. Sparavigna A, R. Forte, F.S. Dio
- Page 15 and 16: A. Sparavigna A, R. Forte, F.S. Dio
- Page 17 and 18: A. Sparavigna A, R. Forte, F.S. Dio
- Page 22 and 23: M. Cavallini, M. PapagniSkin hydrat
- Page 24 and 25: M. Cavallini, M. Papagni5. Altman D
- Page 26 and 27: G. Menchini, C. ComacchiM ethodsO b
- Page 28 and 29: G. Menchini, C. Comacchimentation,
- Page 30 and 31: Impiego di lamine autoadesivedi pol
- Page 32 and 33: Impiego di lamine autoadesive di po
- Page 34 and 35: Impiego di lamine autoadesive di po
- Page 36 and 37: Efficacia, tollerabilità ed accett
- Page 38 and 39: Efficacia, tollerabilità ed accett
- Page 40 and 41: Efficacia, tollerabilità ed accett
- Page 42 and 43: D. AnconaGli studi sulla citotossic
- Page 44 and 45: D. AnconaPRIMADOPOFigura 2. Pazient
- Page 46 and 47: L.Scuderi, L. Francesconi, F. Dinot
- Page 48 and 49: L.Scuderi, L. Francesconi, F. Dinot
- Page 50 and 51: E. Perosino12Figura 1.Lesione macul
- Page 52 and 53: Irsutismo:trattamento con eflorniti
- Page 54 and 55: Irsutismo: trattamento con eflornit
- Page 56 and 57: Irsutismo: trattamento con eflornit
- Page 58 and 59: Irsutismo: trattamento con eflornit
- Page 60 and 61: Irsutismo: trattamento con eflornit
- Page 62 and 63: Irsutismo: trattamento con eflornit
- Page 64 and 65: Una molecola classicain una nuova v
- Page 66 and 67: Microcircolo, cute e antocianosidiA
- Page 68 and 69: Microcircolo, cute e antocianosidiL
- Page 70 and 71:
Microcircolo, cute e antocianosidiG
- Page 72 and 73:
Microcircolo, cute e antocianosidiC
- Page 78:
struzioni agli AutoriIObiettivo del